1 Department Radiation Oncology, Shanghai General Hospital, Shanghai, China.
2 Department Radiation Oncology, Cancer Institute of New Jersey, NJ, USA.
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819841061. doi: 10.1177/1533033819841061.
This article compares the dosimetric differences between jaw tracking and no jaw tracking technique in static intensity-modulated radiation therapy plans of large and small tumors.
Eight plans with large tumor (nasopharyngeal carcinoma, volume range: 510.9 to 768.0 cm) and 8 plans with small tumor (single brain metastasis, volume range: 5.3 to 9.9 cm) treated with jaw tracking on Varian EDGE LINAC were chosen and recalculated with no jaw tracking to study the dosimetric differences. We compared the differences of organ-at-risk doses (Dmax, Dmean), monitor units, and γ passing rate of plan verification (3mm/3%, threshold 10%; 2mm/2%, threshold 10%) between the 2 techniques.
The organ-at-risk doses of nasopharyngeal carcinoma cases having jaw tracking are all less than those with no jaw tracking. The Dmax and Dmean of organ-at-risks reduced 0.61% to 17.65% and 2.17% to 19.32%, P < .05, respectively. In cases with single brain metastasis, the organ-at-risk doses with jaw tracking were also lower than no jaw tracking. The Dmax and Dmean of organ-at-risk doses reduced 0.84% to 1.52% and 0.90% to 1.86%, P < .05, respectively. The monitor units for the large tumor and small tumor were increased by 2.41% and 1.1%, respectively. The γ passing rates (3mm/3%, th10%; 2mm/2%, th10%) of nasopharyngeal carcinoma plans are 99.89% ± 0.06% (jaw tracking) versus 99.56% ± 0.19% (no jaw tracking; P = .127); 97.15% ± 0.98% (jaw tracking) versus 91.90% ± 1.40% (no jaw tracking; P = .000), and the γ passing rates (3mm/3%, th10%; 2mm/2%, th10%) of brain metastasis plans are 99.97% ± 0.05% (jaw tracking) versus 99.44% ± 1.24% (no jaw tracking; P = .251), 98.65% ± 1.27% (jaw tracking) versus 93.35% ± 2.72% (no jaw tracking; P = .000).
Jaw tracking can reduce the dose of organ-at-risks compared to no jaw tracking, and the effect is more significant for plans with large tumor. The γ passing rate of plans with jaw tracking is also higher than the plans with no jaw tracking. Although the monitor units in plans of jaw tracking will increase slightly, it is recommended to use jaw tracking in static intensity-modulated radiation therapy both in large and in small tumors.
本文比较了大、小肿瘤静态调强放疗计划中使用和不使用 jaw tracking 技术的剂量学差异。
选择 8 例大肿瘤(鼻咽癌,体积范围:510.9 至 768.0cm)和 8 例小肿瘤(单发脑转移瘤,体积范围:5.3 至 9.9cm)的 jaw tracking 调强放疗计划,并重新计算无 jaw tracking 的计划,以研究剂量学差异。我们比较了两种技术之间的危及器官剂量(Dmax、Dmean)、监测单位和计划验证的γ通过率(3mm/3%,阈值 10%;2mm/2%,阈值 10%)。
有 jaw tracking 的鼻咽癌病例的危及器官剂量均低于无 jaw tracking 的病例。有 jaw tracking 的危及器官剂量的 Dmax 和 Dmean 分别降低了 0.61%至 17.65%和 2.17%至 19.32%,P<.05。单发脑转移瘤病例的 jaw tracking 组的危及器官剂量也低于无 jaw tracking 组。有 jaw tracking 的危及器官剂量的 Dmax 和 Dmean 分别降低了 0.84%至 1.52%和 0.90%至 1.86%,P<.05。大肿瘤和小肿瘤的监测单位分别增加了 2.41%和 1.1%。鼻咽癌计划的γ通过率(3mm/3%,th10%;2mm/2%,th10%)为 99.89%±0.06%(jaw tracking)与 99.56%±0.19%(无 jaw tracking;P=.127);97.15%±0.98%(jaw tracking)与 91.90%±1.40%(无 jaw tracking;P=.000),脑转移瘤计划的γ通过率(3mm/3%,th10%;2mm/2%,th10%)为 99.97%±0.05%(jaw tracking)与 99.44%±1.24%(无 jaw tracking;P=.251),98.65%±1.27%(jaw tracking)与 93.35%±2.72%(无 jaw tracking;P=.000)。
与不使用 jaw tracking 相比,jaw tracking 可以降低危及器官的剂量,对于大肿瘤的计划效果更为显著。有 jaw tracking 的计划的γ通过率也高于无 jaw tracking 的计划。虽然 jaw tracking 计划的监测单位会略有增加,但建议在大、小肿瘤的静态调强放疗中使用 jaw tracking。